Bavarian Nordic A/S
KVISTGRD, Denmark, November 30 - Bavarian Nordic A/S (OMX: BAVA) announced today that the company expects
to file a New Drug Submission (NDS) for its third-generation smallpox
vaccine, IMVAMUNE(R) with the Canadian Authorities, Health Canada in 2010.
KVISTGRD, Denmark, November 17 - Bavarian Nordic A/S (OMX: BAVA) announced today that BARDA (Biomedical
Advanced Research and Development Authority) has awarded a new contract to
Bavarian Nordic for the development of a freeze-dried version of its
IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40
million.
KVISTGARD, Denmark, November 11 - Today Bavarian Nordic published the company's third quarterly report
2009.
KVISTGAARD, Denmark - Bavarian Nordic A/S (OMX: BAVA) yesterday presented further detailed PROSTVAC(TM) data at the European Cancer Organisation (ECCO), ECCO 15 - 34th ESMO Congress in Berlin, Germany.
KVISTGAARD, Denmark - Bavarian Nordic A/S (OMX: BAVA) announced today that it has signed a contract with the military of an undisclosed EU country for the delivery of a small order for IMVAMUNE(R).
More News
- Bavarian Nordic A/S - Half Year Interim Report 2009
- Bavarian Nordic in Negotiations With the US Authorities for the Further Development of IMVAMUNE(R)
- New Review on PROSTVAC(TM) Published by Key Investigators From NCI
- PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
- Invitation: PROSTVAC(TM) Wrap up
- The Court Supports Bavarian Nordic’s Decision to Start Patent Infringement Case Against Oxford BioMedica
- Bavarian Nordic Announces its Interim Report for the Period 1 January to 31 March 2009
